Publications by authors named "Calogero Vetro"

Claim this Profile
E
Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients.
Matteo Molica, Gema Miralles, Richard Dillon, Mario Annunziata, Faisal Basheer, Calogero Vetro

Am J Hematol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation.
Fabio Guolo, Luana Fianchi, Maria Paola Martelli, Federico Lussana, Francesco Grimaldi, Calogero Vetro

Am J Hematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.
Calogero Vetro, Bruno Garibaldi, Francesco Grimaldi, Patrizia Chiusolo, Carla Filì

Blood Cancer J· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.
Raffaele Palmieri, Fabio Guolo, Luana Fianchi, Felicetto Ferrara, Paola Minetto, Calogero Vetro

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extramedullary Acute Myeloid Leukemia: Evaluating Azacitidine-Venetoclax Combination Outcomes and the Role of Molecular Genetics and Bone Marrow Involvement.
Fanny E Palumbo, Calogero Vetro, Valeria Calafiore, Andrea Duminuco, Cinzia Maugeri

Eur J Haematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study.
Elisabetta Petracci, Francesca Pavesi, Luca Castagna, Patrizia Zappasodi, Cristina Papayannidis, Calogero Vetro

Br J Haematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diffuse large B-cell lymphoma in the new era: prognostic tools for mapping risk.
Andrea Duminuco, Salvatore Scarso, Vittorio Del Fabro, Laura Anastasia Caruso, Gaia Stanzione, Calogero Vetro

Ann Hematol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.
Calogero Vetro, Bruno Garibaldi, Francesco Grimaldi, Patrizia Chiusolo, Carla Filì

Blood Cancer J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vitamin K Antagonists (VKAs) and Novel Oral Anticoagulants (NOACs) Safety Comparison Based on Data from EudraVigilance Database.
Pier Paolo Olimpieri, Fanny Erika Palumbo, Gaetano Giuffrida, Edoardo Milanetti, Cecilia Gozzo, Calogero Vetro

Hematol Rep· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benign purpuric cutaneous eruption in a young patient with AML treated with CPX-351.
Fanny Erika Palumbo, Calogero Vetro, Cinzia Maugeri, Marina Silvia Parisi, Andrea Duminuco

Leuk Lymphoma· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experience.
Roberto Cairoli, Lorenzo Del Castello, Silvia Imbergamo, Elisabetta Pierdomenico, Cristina Papayannidis, Calogero Vetro

Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does the Timing of Response Impact the Outcome of Relapsed/Refractory Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents? A Proof of Concept from a Monocentric Observational Study.
Ermelinda Longo, Fanny Erika Palumbo, Andrea Duminuco, Laura Longo, Daniela Cristina Vitale, Calogero Vetro

J Clin Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Old Therapy, New Questions: Rethinking Phlebotomy in a Pharmacologic Landscape.
Andrea Duminuco, Patrick Harrington, Vittorio Del Fabro, Elvira Scalisi, Gabriella Santuccio, Calogero Vetro

Pharmaceuticals (Basel)· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Length of Washout Period After Remission Does Not Influence Relapse Risk in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents Combined with Venetoclax.
Fanny Erika Palumbo, Andrea Duminuco, Laura Longo, Daniela Cristina Vitale, Cinzia Maugeri, Calogero Vetro

J Clin Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Outcomes in -ITD Mutated Acute Myeloid Leukemia: Impact of NPM1 Mutations and Allogeneic Transplantation in a Retrospective Unicentric Cohort.
Veronica Vecchio, Andrea Duminuco, Salvatore Leotta, Elisa Mauro, Cinzia Maugeri, Calogero Vetro

J Clin Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging Therapeutic Approaches for Anemia in Myelofibrosis.
Helen T Chifotides, Andrea Duminuco, Elena Torre, Calogero Vetro, Patrick Harrington

Curr Hematol Malig Rep· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents.
Giovanni Marconi, Elisabetta Petracci, Giuseppe Lanzarone, Calogero Vetro, Maria Paola Martelli

Am J Hematol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial.
Domenico Russo, Nicola Polverelli, Simona Bernardi, Stella Santarone, Mirko Farina, Calogero Vetro

Lancet Haematol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study.
Salvatore Leotta, Uros Markovic, Andrea Duminuco, Antonino Mulè, Ferdinando Porretto, Calogero Vetro

Ann Hematol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Access for Medicines in ITALY: The Case of Ruxolitinib for Patients with Graft-Versus-Host Disease.
Lucia Gozzo, Salvatore Leotta, Giovanni Luca Romano, Calogero Vetro, Andrea Duminuco

J Clin Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study.
Francesco Malfona, Ilaria Tanasi, Matteo Piccini, Cristina Papayannidis, Vincenzo Federico, Calogero Vetro

Haematologica· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pharmacotherapeutic management of patients with myelofibrosis: looking beyond JAK inhibitors.
Andrea Duminuco, Calogero Vetro, Cesarina Giallongo, Giuseppe Alberto Palumbo

Expert Opin Pharmacother· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential clinical impact of T-cell lymphocyte kinetics monitoring in patients with B cell precursors acute lymphoblastic leukemia treated with blinatumomab: a single-center experience.
Andrea Duminuco, Uros Markovic, Nunziatina Laura Parrinello, Luca Lo Nigro, Elisa Mauro, Calogero Vetro

Front Immunol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A case of high-risk AML in a patient with advanced systemic mastocytosis.
Manlio Fazio, Calogero Vetro, Uroš Markovic, Andrea Duminuco, Marina Parisi

Clin Case Rep· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance Data.
Lucia Gozzo, Antonella Nardo, Serena Brancati, Antongiulio Judica, Andrea Duminuco, Calogero Vetro

Healthcare (Basel)· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis